ReviewJournal of biosciences2008
Preventive strategies for frequent outbreaks of Japanese encephalitis in Northern India.
Review in Journal of biosciences, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 44 citations in OpenAlex.
- Preventive effects of arctigenin from Arctium lappa L against LPS-induced neuroinflammation and cognitive impairments in mice.Metabolic brain disease · 2022Article
- Decreases in Both the Seroprevalence of Serum Antibodies and Seroprotection against Japanese Encephalitis Virus among Vaccinated Children.Virologica Sinica · 2019Article
- Japanese Encephalitis: A Brief Review on Indian Perspectives.The open virology journal · 2018Review
- Disappearance ofJournal of arthropod-borne diseases · 2017Article
- Identifying sources, pathways and risk drivers in ecosystems of Japanese Encephalitis in an epidemic-prone north Indian district.PloS one · 2017Article
- Complete genome sequence of two genotype III Japanese encephalitis virus isolates from West Bengal, India.The Indian journal of medical research · 2015Article
- DDT & deltamethrin resistance status of known Japanese encephalitis vectors in Assam, India.The Indian journal of medical research · 2013Article
- Pediatricians' perceptions of vaccine effectiveness and safety are significant predictors of vaccine administration in India.International health · 2013Article
- Clinical presentation, etiology, and survival in adult acute encephalitis syndrome in rural Central India.Clinical neurology and neurosurgery · 2013Article
- Epidemiological concordance of Japanese encephalitis virus infection among mosquito vectors, amplifying hosts and humans in India.Epidemiology and infection · 2013Article
- Inhibition of HIV-1 Integrase gene expression by 10-23 DNAzyme.Journal of biosciences · 2012Article
- Mass scale screening of common arboviral infections by an affordable, cost effective RT-PCR method.Asian Pacific journal of tropical biomedicine · 2012Article
- Larvicidal, repellent, and ovicidal activity of marine actinobacteria extracts against Culex tritaeniorhynchus and Culex gelidus.Parasitology research · 2011Article
- Introduction of Japanese encephalitis virus genotype I, India.Emerging infectious diseases · 2011Article
- Antiviral and neuroprotective role of octaguanidinium dendrimer-conjugated morpholino oligomers in Japanese encephalitis.PLoS neglected tropical diseases · 2010Article
- Development of a vaccine to prevent Japanese encephalitis: a brief review.International journal of general medicine · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Japanese encephalitis (JE) remains the most important cause of acute viral encephalitis and continues to spread to hitherto unaffected regions like Indonesia, Pakistan and Australia. Approximately 60% of the world population inhabits JE endemic areas. Despite its restricted range mostly in the developing countries,a high annual incidence of 50,000 cases and about 10,000 deaths has been reported. Disease can be fatal in 25% ases. Magnitude of the problem is even more alarming since the survivors are left with serious long-term neuropsychiatric sequelae. Almost every two years,epidemics of JE occur in Indian subcontinent with a high mortality. JE virus infection results in different disease manifestations in host from mild subclinical febrile illness to clinical infections leading to encephalitis. No antiviral treatment is so far available for JE. The prevention of JE can be achieved by controlling the vector or by immunization regime. The vector control in the rural areas,which are the worst affected ones,is practically almost impossible. Three vaccines that have been implicated against JE include inactivated mouse brain derived, inactivated cell culture derived and cell culture derived live attenuated JE vaccine. But each has its own limitation. Currently,attempts to synthesize recombinant DNA vaccine are being made. New therapeutics are on the way of development like use of minocycline, short interfering RNA, arctigenin, rosmarinic acid, DNAzymes etc. However,the immune mechanisms that lead to JE are complex and need to be elucidated further for the development of therapeutics as well as safe and efficacious JE vaccines.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.